早期乳腺癌分子复发检测的评估
这项前瞻性多中心研究评估了循环肿瘤DNA(ctDNA)检测早期乳腺癌分子复发的临床有效性。研究纳入170例早期乳腺癌患者,其中101例形成主要队列。结果显示,随访中检测到ctDNA与复发显著相关(风险比25.2;95%CI 6.7-95.6;P<.001),中位领先时间为10.7个月。
要点
- 随访中ctDNA检测与早期乳腺癌复发高风险相关(HR 25.2)。
- ctDNA检测较临床复发中位领先10.7个月。
- 脑转移单独发生时ctDNA检出率较低(1/6)。
核心结论
- 随访中检测到ctDNA与早期乳腺癌未来复发高风险相关。
- 需要前瞻性研究评估分子复发检测指导辅助治疗的潜力。
研究设计与样本
- 前瞻性、多中心、样本收集与验证研究,在英国5个医学中心开展。
- 招募170例早期乳腺癌女性,其中101例鉴定出突变形成主要队列。
- 主要队列中位随访35.5个月(四分位距27.9-43.0个月)。
主要发现
- 主要队列中随访期ctDNA检测与复发相关(风险比25.2;95%CI 6.7-95.6;P<.001)。
- 诊断时未治疗前ctDNA检测与无复发生存相关(风险比5.8;95%CI 1.2-27.1;P=.01)。
- 合并队列中ctDNA检测较临床复发中位领先10.7个月(95%CI 8.1-19.1个月)。
- 远处颅外转移复发患者中22/23例(96%)通过ctDNA检测发现。
- 仅脑转移患者中ctDNA检测发现1/6例(17%)。
临床怎么用
- 对早期乳腺癌患者,可考虑系列血浆ctDNA检测以监测分子复发。
- ctDNA检测领先临床复发约10.7个月,可能为干预提供时间窗。
- 脑转移单独发生时ctDNA检测敏感性较低,需结合影像学。
局限性
- 需要前瞻性研究验证ctDNA检测指导辅助治疗的价值。
- 仅脑转移患者中ctDNA检出率低,可能漏诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Current treatment cures most cases of early-stage, primary breast cancer. However, better techniques are required to identify which patients are at risk of relapse. OBJECTIVE: To assess the clinical validity of molecular relapse detection with circulating tumor DNA (ctDNA) analysis in early-stage breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This prospective, multicenter, sample collection, validation study conducted at 5 United Kingdom medical centers from November 24, 2011, to October 18, 2016, assessed patients with early-stage breast cancer irrespective of hormone receptor and ERBB2 (formerly HER2 or HER2/neu) status who were receiving neoadjuvant chemotherapy followed by surgery or surgery before adjuvant chemotherapy. The study recruited 170 women, with mutations identified in 101 patients forming the main cohort. Secondary analyses were conducted on a combined cohort of 144 patients, including 43 patients previously analyzed in a proof of principle study. INTERVENTIONS: Primary tumor was sequenced to identify somatic mutations, and personalized tumor-specific digital polymerase chain reaction assays were used to monitor these mutations in serial plasma samples taken every 3 months for the first year of follow-up and subsequently every 6 months. MAIN OUTCOMES AND MEASURES: The primary end point was relapse-free survival analyzed with Cox proportional hazards regression models. RESULTS: In the main cohort of 101 female patients (mean [SD] age, 54 [11] years) with a median follow-up of 35.5 months (interquartile range, 27.9-43.0 months), detection of ctDNA during follow-up was associated with relapse (hazard ratio, 25.2; 95% CI, 6.7-95.6; P < .001). Detection of ctDNA at diagnosis, before any treatment, was also associated with relapse-free survival (hazard ratio, 5.8; 95% CI, 1.2-27.1; P = .01). In the combined cohort, ctDNA detection had a median lead time of 10.7 months (95% CI, 8.1-19.1 months) compared with clinical relapse and was associated with relapse in all breast cancer subtypes. Distant extracranial metastatic relapse was detected by ctDNA in 22 of 23 patients (96%). Brain-only metastasis was less commonly detected by ctDNA (1 of 6 patients [17%]), suggesting relapse sites less readily detectable by ctDNA analysis. CONCLUSIONS AND RELEVANCE: The findings suggest that detection of ctDNA during follow-up is associated with a high risk of future relapse of early-stage breast cancer. Prospective studies are needed to assess the potential of molecular relapse detection to guide adjuvant therapy.
引用
- Garcia-Murillas I, Chopra N, Comino-Méndez I, et al. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol. 2019. PMID: 31369045. doi:10.1001/jamaoncol.2019.1838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。